MPYS protein stimulants - Pipeline Insight, 2024

This “MPYS protein stimulants - Pipeline Insight, 2024” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in MPYS protein stimulants pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

MPYS protein stimulants Understanding

MPYS protein stimulants: Overview

Stimulator of interferon genes (STING), also known as transmembrane protein 173 (TMEM173) and MPYS/MITA/ERIS is a protein that in humans is encoded by the STING1 gene. STING plays an important role in innate immunity. STING induces type I interferon production when cells are infected with intracellular pathogens, such as viruses, mycobacteria and intracellular parasites. Type I interferon, mediated by STING, protects infected cells and nearby cells from local infection by binding to the same cell that secretes it (autocrine signaling) and nearby cells (paracrine signaling.) It thus plays an important role, for instance, in controlling norovirus infection.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence MPYS protein stimulants R&D. The therapies under development are focused on novel approaches for MPYS protein stimulants.

MPYS protein stimulants Emerging Drugs Chapters

This segment of the MPYS protein stimulants report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

MPYS protein stimulants Emerging Drugs

MK 1454: Merck & Co STING agonist MK-1454 binds to STING and activates the STING pathway, which promotes IKK-related kinase TANK-binding kinase 1 (TBK1) signaling and activates nuclear factor-kappa B (NF-kB) and interferon regulatory factor 3 (IRF3) in immune cells in the tumor microenvironment; this leads to the production of pro-inflammatory cytokines, including interferons (IFNs). Specifically, expression of IFN-beta (IFNb) enhances the cross-presentation of tumor-associated antigens by CD8alpha-positive and CD103-positive dendritic cells (DCs) to cytotoxic T lymphocytes (CTLs). This results in a CTL-mediated immune response against tumor cells and causes tumor cell lysis. Currently, it is in Phase II stage of clinical trial evaluation to treat squamous cellcancer.

SYNB1891: Synlogic SYNB1891 is an investigational drug for the intra-tumoral treatment of solid tumors and lymphoma, composed of an engineered Synthetic Biotic strain of E. coli Nissle that produces cyclic di-AMP (CDA), a stimulator of the STING (STimulator of INterferon Genes) pathway. This mechanism can play a critical role in the initiation of an anti-tumor immune response via activation of APCs and presentation of tumor antigens. The bacterial chassis of SYNB1891 also stimulates the innate immune system by several other mechanisms, including via Toll-like receptors (TLRs), potentially adding to the magnitude of the overall immune response. While SYNB1891 has been engineered with safety features that are designed to prevent its replication unless supplemented with specific nutrients, the bacteria remain active for several days within the injected tumor to stimulate a local immune response. SYNB1891 is being evaluated in a Phase 1 clinicaltrial.

MPYS protein stimulants: Therapeutic Assessment

This segment of the report provides insights about the different MPYS protein stimulants drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on MPYS protein stimulants

There are approx. 20+ key companies which are developing the MPYS protein stimulants. The companies which have their MPYS protein stimulants drug candidates in the most advanced stage, i.e. Phase II include, Merck & Co.

Phases

This report covers around 20+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

MPYS protein stimulants pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

MPYS protein stimulants: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses MPYS protein stimulants therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging MPYS protein stimulants drugs.

MPYS protein stimulants Report Insights

• MPYS protein stimulants Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

MPYS protein stimulants Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing MPYS protein stimulants drugs?
• How many MPYS protein stimulants drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of MPYS protein stimulants?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the MPYS protein stimulants therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for MPYS protein stimulants and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Merck & Co
• Synlogic
• Chinook Therapeutics
• Takeda
• Codiak BioSciences
• ImmuneSensor
• Shanghai De Novo Pharmatech
• Onco NanoMedicine
• Eternity Bioscience
• X-37
• F-star Therapeutics
• Mavupharma
• Bristol-Myers Squibb
• GlaxoSmithKline
• LIDDS
• Trillium Therapeutics Inc
• Silicon Therapeutics
• Mersana Therapeutics
• Actym Therapeutics
• Stimunity
• Curadev Pharma

Key Products

• MK 1454
• SYNB1891
• TTI 10001
• SNX-281
• ADU S100
• STACT-TREX1
• NZ-IO-STING
• TAK 676
• GSK 532
• BMS 986301
• CRD 5500
• exoSTING
• IMSA 101
• MAVU 104
• DN 015089
• SB 11312

Research programme: c GAS/STING agonists- ONM501

• TAK 500
• ONM 500
• Non-CDN STING agonist

This product will be delivered within 2-4 business days.